Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome

Clinical Endocrinology

Volumn 68, Issue 6, 2008, Pages 919-925

  Festen, D A M ^a   Wevers, M ^a   Lindgren, A C ^b   Bohm B ^b   Otten, B J ^c   Wit, J M ^d   Duivenvoorden, H J ^e   Hokken Koelega, A C S ^a,e  

^a Dutch Growth Foundation   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ARTICLE; CHILD DEVELOPMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INFANT; MALE; MENTAL DEVELOPMENT; MOTOR DEVELOPMENT; PRADER WILLI SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 43949109935     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03126.x     Document Type: Article

References (29)

1. 1 Bekx, T., Carrel, A.L., Shriver, T.C., Li, Z. & Allen, D.B. (2003) Decreased energy expenditure is caused by abnormal body composition in infants with Prader–Willi syndrome. Journal of Pediatrics, 143, 372–376.
2. 2 Eiholzer, U., Blum, W.F. & Molinari, L. (1999) Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader–Labhart–Willi syndrome. Journal of Pediatrics, 134, 222–225.
3. 3 Swaab, D.F., Purba, J.S. & Hofman, M.A. (1995) Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader–Willi syndrome. Journal of Clinical Endocrinology and Metabolism, 80, 573–579.
4. 4 Swaab, D.F. (1997) Prader–Willi and the hypothalamus. Acta Paediatrica Supplementum, 423, 50–54.
5. 5 Young, I.D. (1995) Diagnosing Prader–Willi syndrome. Lancet, 345, 1590.
6. 6 Nicholls, R.D. (1993) Genomic imprinting and uniparental disomy in Angelman and Prader–Willi syndrome. American Journal of Medical Genetics, 46, 16–25.
7. 7 Myers, S.E., Carrel, A.L., Whitman, B.Y. & Allen, D.B. (2000) Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader–Willi syndrome. Journal of Pediatrics, 137, 42–49.
8. 8 Myers, S.E., Carrel, A.L., Whitman, B.Y. & Allen, D.B. (1999) Physical effects of growth hormone treatment in children with Prader–Willi syndrome. Acta Paediatrica Supplementum, 433, 112–114.
9. 9 Carrel, A.L., Myers, S.E., Whitman, B.Y. & Allen, D.B. (1999) Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader–Willi syndrome: a controlled study. Journal of Pediatrics, 215–221.
10. 10 Eiholzer, U., Gisin, R., Weinmann, C., Kriemler, S., Steinert, H., Torresani, T., Zachmann, M. & Prader, A. (1998) Treatment with human growth hormone in patients with Prader–Labhart–Willi syndrome reduces body fat and increases muscle mass and physical performance. European Journal of Pediatrics, 157, 368–377.
11. 11 Lindgren, A.C., Hagenas, L., Muller, J., Blichfeldt, S., Rosenborg, M., Brismar, T. & Ritzen, E.M. (1997) Effects of growth hormone treatment on growth and body composition in Prader–Willi syndrome: a preliminary report. Acta Paediatrica Supplementum, 423, 60–62.
12. 12 Whitman, B.Y., Myers, S., Carrel, A. & Allen, D. (2002) The behavioral impact of growth hormone treatment for children and adolescents with Prader–Willi syndrome: a 2‐year controlled study. Pediatrics, 109, E35.
13. 13 Dittrich, B., Robinson, W.P., Knoblauch, H., Buiting, K., Schmidt, K., Gillessen‐Kaesbach, G. & Horsthemke, B. (1992) Molecular diagnosis of the Prader–Willi and Angelman syndromes by detection of parent‐of‐origin specific DNA methylation in 15q11–13. Human Genetics, 90, 313–315.
14. 14 Lindgren, A.C., Grandell, U., Ritzen, E.M. & Anvret, M. (1996) Diagnosis of the Prader–Willi syndrome by proving absence of the unmethylated PW71 DNA fragment. Acta Paediatrica, 38, 418–421.
15. 15 Carrel, A.L., Moerchen, V., Myers, S.E., Bekx, T., Whitman, B.Y. & Allen, D.B. (2004) Growth hormone improves mobility and body composition in infants and toddlers with Prader–Willi syndrome. Journal of Pediatrics, 145, 744–749.
16. 16 Myers, S.E., Whitman, B.Y., Carrel, A.L., Moerchen, V., Bekx, T. & Allen, D.B. (2007) Two years of growth hormone therapy in young children with Prader–Willi syndrome: physical and neurodevelopmental benefits. American Journal of Medical Genetics, 143, 443–448.
17. 17 Fredriks, A., Van Buuren, S. & Burgmeijer, R. (2000) Continuing positive secular growth change in the Netherlands 1955–1997. Pediatric Research, 47, 316–323.
18. 18 Bayley, N. (1993) Bayley Scales of Infant Development (2nd edition). The Psychological Corporation, San Antonio, TX.
19. 19 Van der Meulen, B.F., Ruiter, S.A.J., Lutje Spelberg, H.C. & Smrkovsky, M. (2002) Bayley Scales of Infant Development‐II [Dutch version]. Swets & Zeitlinger BV, Lisse, the Netherlands.
20. 20 Hokken‐Koelega, A.C., Hackeng, W.H., Stijnen, T., Wit, J.M., De Muinck Keizer‐Schrama, S.M. & Drop, S.L. (1990) Twenty‐four‐hour plasma growth hormone (GH) profiles, urinary excretion, and plasma insulin‐like growth factor‐I and ‐II levels in pre‐pubertal children with chronic renal insufficiency and severe growth retardation. Journal of Clinical Endocrinology and Metabolism, 71, 688–695.
21. 21 Juul, A., Bang, P., Hertel, N.T., Main, K., Dalgaard, P., Jorgensen, K., Muller, J., Hall, K. & Skakkebaek, N.E. (1994) Serum insulin‐like growth factor‐I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism, 78, 744–752.
22. 22 Festen, D.A.M., De Weerd, A.W., Van Den Bossche, R.A.S., Joosten, K., Hoeve, H. & Hokken‐Koelega, A.C.S. (2006) Sleep‐related breathing disorders in prepubertal children with Prader–Willi syndrome and effects of growth hormone treatment. Journal of Clinical Endocrinology and Metabolism, 91, 4911–4915.
23. 23 Festen, D.A.M., Van Toorenenbergen, A., Duivenvoorden, H.J. & Hokken‐Koelega, A.C.S. (2007) Adiponectin levels in pre‐pubertal children with Prader–Willi syndrome before and during growth hormone therapy. Journal of Clinical Endocrinology and Metabolism, 92, 1549–1554.
24. 24 Festen, D.A.M., Visser, T.J., Otten, B.J., Wit, J.M., Duivenvoorden, H.J. & Hokken‐Koelega, A.C.S. (2007) Thyroid hormone levels in children with Prader–Willi syndrome before and during growth hormone treatment. Clinical Endocrinology, 67, 449–456.
25. 25 Aughton, D.J. & Cassidy, S.B. (1990) Physical features of Prader–Willi syndrome in neonates. American Journal of Diseases in Childhood, 144, 1251–1254.
26. 26 Eiholzer, U., L’Allemand, D., Schlumpf, M., Rousson, V., Gasser, T. & Fusch, C. (2004) Growth hormone and body composition in children younger than 2 years with Prader Willi syndrome. Journal of Pediatrics, 144, 753–758.
27. 27 Ranke, M.B., Lindberg, A., Albertsson‐Wikland, K., Wilton, P., Price, D.A. & Reiter, E.O. (2005) Increased response, but lower responsiveness, to growth hormone (GH) in very young children with idiopathic growth hormone deficiency: analysis of data from KIGS. Journal of Clinical Endocrinology and Metabolism, 90, 1966–1971.
28. 28 Gale, C.R., O’Callaghan, F.J., Godfrey, K.M., Law, C.M. & Martyn, C.N. (2004) Critical periods of brain growth and cognitive function in children. Brain, 127, 321–329.
29. 29 Adem, A., Jossan, S.S., D’Argy, R., Gillberg, P.G., Nordberg, A., Winblad, B. & Sara, V. (1989) Insulin‐like growth factor 1 (IGF‐1) receptors in the human brain: quantitative autoradiographic localization. Brain Research, 503, 299–303.